Mr. Harmon is a strategic life sciences consultant driving growth and transformation through data-driven insights, market intelligence, and technology-enabled business solutions that accelerate discovery, optimize investments, and scale breakthrough innovations across global markets. As an Associate Manager at Sia/LBG, he develops strategic roadmaps for public-private life science partnerships across US, EU, and GCC markets, leads market intelligence initiatives with specialized focus on cell and gene therapy analysis, and provides M&A and capital strategy consulting. His work includes comprehensive financial modeling and competitive benchmarking, and he has helped secure and manage over $275M in client funding, delivering strategic recommendations that align multi-million-dollar investments with health and economic development priorities.
Prior to joining Sia/LBG, Mr. Harmon gained diverse experience across the life sciences value chain, including portfolio and program management supporting $80M in R&D capital deployment at Horizon Therapeutics (acquired by Amgen), operational excellence and knowledge management initiatives at Pfizer, and comprehensive financial due diligence as a Deal Analyst with NC State University’s Wolfpack Investor Network (WIN), where he conducted valuation modeling and market analysis for early-stage investments across diverse industries. He also has extensive academic research experience in neurodevelopmental genetics and drug discovery, complemented by over six years of operations management and logistics expertise, including process optimization and cross-functional team leadership.
Mr. Harmon holds an MBA in Finance, a Master of Microbial Biotechnology (MMB), and a B.S. in Molecular Biology from North Carolina State University. He is a certified Project Management Professional (PMP®) and Six Sigma Black Belt Professional (SSBBP®) and regularly presents his market analysis and state-of-the-industry assessments at international industry conferences.